Drug application
HALFLYTELY (BISACODYL, POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE and 2 more)
Drugs@FDA NDA 021551 · BRAINTREE
Key facts
| Drug name | HALFLYTELY |
|---|---|
| Active ingredients | BISACODYL, POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE |
| Application type | NDA |
| Application number | 021551 |
| Company | BRAINTREE |
| Dosage forms | FOR SOLUTION, TABLET, DELAYED RELEASE, ORAL |
| Strength | 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | May 10, 2004 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: